Health committee  Over the course of all the business we do, we have engaged with NACI, but as it relates to the current four-month dose schedule recommendation, we have not been in contact with them.

Health committee  Right now, a company in Vancouver was critical in our development of this vaccine by providing IP and a licence for that IP that was related to the lipid nanoparticle. While they are not directly supplying us with any part of the supply chain their know-how and expertise was crit

Health committee  The negotiations and additional details on the negotiations are confidential, and unfortunately I cannot share those details.

Health committee  To be successful going forward in creating more resiliency here in Canada, the government needs to create conditions that foster innovation and support investment. We are competing on a global stage and are apparently woefully behind our peers. We need to start with incremental s

Health committee  Mr. Chair, I'd like to remind the member that the U.S. situation is different than Canada's. Going back to his earlier question and comment, the U.S. has continuously supported innovation in the life sciences sector and, therefore, has a different reason to discuss and potentiall

Health committee  The answer is that prices remain confidential.

Health committee  We were always anticipating a Q1 launch, assuming that Health Canada gave a favourable review of our dossier.

Health committee  As I responded earlier, prices are confidential, so we will not be—

Health committee  As I mentioned in our opening statements, around the world, including Canada, Pfizer has committed on a quarterly basis to what the delivery schedule will be.

Health committee  The volumes that are in our contract, which we have publicly disclosed and I'd be happy to reiterate now, are what determines our delivery schedule.

Health committee  As mentioned before, we have not been in touch with NACI.

Health committee  It is Pfizer's belief that the product monograph, which has a 21-day schedule between doses, is the right approach.

Health committee  Mr. Chair, could I ask the member to clarify the timing of the question regarding when we engaged and how we engaged with the government?

Health committee  Yes, they did, but we wanted to move as fast as the speed of science would allow, and having full autonomy over our manufacturing process was vital to be able to do that. Subsequently, as recently as a month ago, we have undertaken a second evaluation of Canadian capabilities t

Health committee  Which part of the process? Mr. Chair, I'd like to understand which part of the process, because as I provided in my opening remarks, there are over 19 different countries that are involved in the manufacture of this. If we're specifically talking about fill-finish, then we are lo